Bayer Fortifies Branding In OTC Naproxen Market With Win In Trademark Litigation
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Bayer convinces federal court to affirm USPTO appeal board decision to cancel competitor Belmora’s Flanax US naproxen product trademark because the firm used packaging that resembled a Bayer product with the same name sold in Mexico. The ruling could provide standing for owners of foreign marks to assert priority rights over similar US marks, according to a patent attorney.